VRTX Vertex Pharmaceuticals Incorporated Stock Quote

VRTX [NASD]

Index	S&P 500	P/E	26.79	EPS (ttm)	9.49	Insider Own	0.20%	Shs Outstand	255.10M	Perf Week	8.15%
Market Cap	63.46B	Forward P/E	16.67	EPS next Y	15.25	Insider Trans	-15.04%	Shs Float	254.81M	Perf Month	-11.74%
Income	2.45B	PEG	2.46	EPS next Q	3.58	Inst Own	93.00%	Short Float	1.34%	Perf Quarter	9.92%
Sales	7.95B	P/S	7.98	EPS this Y	-12.50%	Inst Trans	1.03%	Short Ratio	2.06	Perf Half Y	35.71%
Book/sh	42.76	P/B	5.94	EPS next Y	7.24%	ROA	18.70%	Target Price	293.15	Perf Year	17.48%
Cash/sh	33.00	P/C	7.70	EPS next 5Y	10.90%	ROE	24.70%	52W Range	176.36 - 292.75	Perf YTD	15.74%
Dividend	-	P/FCF	25.89	EPS past 5Y	85.00%	ROI	22.50%	52W High	-13.18%	Beta	0.59
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	34.80%	Gross Margin	88.00%	52W Low	44.12%	ATR	8.96
Employees	3900	Current Ratio	4.80	Sales Q/Q	21.60%	Oper. Margin	36.90%	RSI (14)	47.03	Volatility	3.38% 3.05%
Optionable	Yes	Debt/Eq	0.05	EPS Q/Q	18.50%	Profit Margin	30.80%	Rel Volume	0.94	Prev Close	246.72
Shortable	Yes	LT Debt/Eq	0.05	Earnings	May 05 AMC	Payout	0.00%	Avg Volume	1.65M	Price	254.17
Recom	2.10	SMA20	-3.62%	SMA50	-2.26%	SMA200	16.28%	Volume	1,558,246	Change	3.02%

May-06-22

Downgrade

Robert W. Baird

Outperform → Neutral

$250

May-03-22

Upgrade

Morgan Stanley

Underweight → Equal-Weight

$250

Feb-03-22

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$269

Jan-27-22

Reiterated

Wolfe Research

Outperform

$271 → $282

Jan-27-22

Reiterated

Stifel

Hold

$213 → $222

Jan-27-22

Reiterated

RBC Capital Mkts

Outperform

$268 → $269

Jan-27-22

Reiterated

Morgan Stanley

Underweight

$203 → $208

Jan-27-22

Reiterated

JP Morgan

Overweight

$260 → $288

Jan-20-22

Upgrade

BMO Capital Markets

Market Perform → Outperform

$202 → $274

Dec-09-21

Initiated

Wells Fargo

Overweight

$270

Nov-19-21

Initiated

BMO Capital Markets

Market Perform

$202

Nov-19-21

Downgrade

Piper Sandler

Overweight → Neutral

$323 → $218

Sep-09-21

Downgrade

Stifel

Buy → Hold

$244 → $213

Sep-07-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$202

Jul-20-21

Downgrade

SVB Leerink

Mkt Perform → Underperform

$170

Jul-19-21

Resumed

Wolfe Research

Outperform

$252

Jul-01-21

Initiated

Raymond James

Mkt Perform

Jun-11-21

Downgrade

Daiwa Securities

Outperform → Neutral

$210

Feb-23-21

Upgrade

Robert W. Baird

Neutral → Outperform

$220 → $252

Feb-02-21

Reiterated

H.C. Wainwright

Buy

$315 → $275

May-16-22 02:23PM	CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs Zacks
May-14-22 06:30AM	Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now Motley Fool
May-12-22 09:11AM	Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News Zacks
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates Zacks
May-09-22 11:05AM	Alcon (ALC) to Report Q1 Earnings: What's in the Cards? Zacks -7.45%
06:00AM	Is Vertex Pharmaceuticals' Billion-Dollar Business Getting Even Bigger? Motley Fool
05:54AM	3 Safe Stocks to Buy That Are Crushing the Market Motley Fool
May-06-22 03:20PM	Stock Market Extends Losses On Jobs Reports, Rising Yields; Materials, Real Estate Add To Woes Investor's Business Daily
01:23PM	Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 Results Zacks
12:43PM	Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline Zacks
12:11PM	Indexes Open Lower, Continue Sell-Off; These Industry Groups Are Moving On Earnings Investor's Business Daily
11:37AM	Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates Zacks
11:02AM	Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss Zacks
10:56AM	STERIS (STE) to Report Q4 Earnings: What's in the Cards? Zacks
10:37AM	Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked Zacks
09:55AM	Apellis (APLS) Hit By Wider-Than-Expected Q1 Loss, Revenues Top Zacks
09:40AM	Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year? Zacks
08:22AM	Dow Jones Futures Fall After Stocks Plunge, Treasury Yields Soar In Delayed Fed Reaction Investor's Business Daily
07:00AM	Stocks That Lift This JPMorgan Fund In Down Market Investor's Business Daily
02:03AM	Vertex Pharmaceuticals (VRTX) Q1 2022 Earnings Call Transcript Motley Fool
May-05-22 05:15PM	Vertex Pharmaceuticals (VRTX) Q1 Earnings Miss Estimates Zacks
05:06PM	Why Vertex Pharma's Pipeline Has Never Been More Important Investor's Business Daily
04:01PM	Vertex Reports First Quarter 2022 Financial Results Business Wire
11:14AM	Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 137% Simply Wall St.
05:52AM	This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better Motley Fool
May-04-22 03:19PM	Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More Zacks
02:21PM	Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss Zacks
01:39PM	Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News Zacks
01:22PM	Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark Zacks
11:39AM	Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies Zacks
11:07AM	TEVA Matches Q1 Earnings Estimates, Lowers 2022 Sales View Zacks
08:42AM	Should You Buy Vertex (VRTX) Ahead of Earnings? Zacks
07:02AM	5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week Zacks
06:00AM	How Bad Is This News for Vertex Pharmaceuticals? Motley Fool
May-03-22 01:00PM	Onconova (ONTX) to Report Q1 Earnings: What's in the Cards? Zacks
11:53AM	Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates Zacks
10:55AM	Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig Zacks
10:47AM	What Awaits Meridian Bioscience (VIVO) This Earnings Season? Zacks
06:37AM	Cardinal Health (CAH) to Post Q3 Earnings: What's in Store? Zacks
06:35AM	AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store? Zacks
May-02-22 04:32PM	Dow Jones Gains; These Warren Buffett Stocks Charge; Pharma Leader Hit By This Surprise Move Investor's Business Daily
03:58PM	Tesla, Lilly, Microsoft Fight Sell-Off As Indexes Search For Bottom Investor's Business Daily
03:21PM	Vertex (VRTX) to Report Q1 Earnings: What's in the Cards? Zacks
01:38PM	Dow Jones Slumps 200 Points, But Warren Buffett Stock Chevron Bucks The Trend; 2 Hot Steel Stocks Test Key Level Investor's Business Daily
01:34PM	FDA orders stop to Vertex diabetes study American City Business Journals
01:11PM	Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold Benzinga
11:49AM	Vertex Falls After FDA Halts Diabetes Study in Surprise Move Bloomberg
11:10AM	Is a Beat in Store for Zoetis (ZTS) This Earnings Season? Zacks
11:04AM	Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates Zacks
10:44AM	How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings? Zacks
10:26AM	Is a Beat Likely for Moderna (MRNA) This Earnings Season? Zacks
10:10AM	5 Best Stocks in Nasdaq ETF That Gained in April Zacks
10:01AM	DaVita (DVA) to Report Q1 Earnings: What's in the Offing? Zacks
08:30AM	Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes Business Wire
06:22AM	The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen Zacks
06:02AM	3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030 Motley Fool
Apr-30-22 09:05AM	2 Biotech Stocks to Buy and Hold for 10 Years Motley Fool
Apr-29-22 03:12PM	AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates Zacks
02:25PM	Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates Zacks
12:29PM	Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down Zacks
11:05AM	Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales Zacks
07:43AM	5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates Zacks
07:35AM	5 Top Stocks for May Motley Fool
Apr-28-22 03:02PM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
02:35PM	BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates Zacks
11:12AM	Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises Zacks
10:44AM	Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute Zacks
Apr-27-22 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know Zacks
12:17PM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? Zacks
11:49AM	BD (BDX) Gears Up for Q2 Earnings: What's in the Offing? Zacks
11:37AM	Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up Zacks
11:01AM	Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase Zacks
Apr-26-22 12:34PM	Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates Zacks
11:48AM	Quidel (QDEL) to Report Q1 Earnings: What's in the Offing? Zacks
10:15AM	Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth Zacks
09:46AM	Is a Beat Likely for AbbVie (ABBV) This Earnings Season? Zacks
Apr-25-22 01:16PM	Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug Zacks
11:46AM	Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs Zacks
09:02AM	Glaxo (GSK) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-22-22 02:58PM	CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards? Zacks
01:19PM	Apellis (APLS) Thrives on Empaveli, Stiff Competition a Woe Zacks
11:36AM	Intercept (ICPT) Outperforms Industry in 3 Months: What Lies Ahead? Zacks
07:39AM	The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals Zacks
Apr-21-22 05:50PM	Vertex Pharmaceuticals (VRTX) Stock Moves -1.26%: What You Should Know Zacks
04:05PM	Vertex to Announce First Quarter 2022 Financial Results on May 5 Business Wire
09:58AM	What to Expect From Centene (CNC) this Earnings Season? Zacks
09:32AM	J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy Zacks
Apr-20-22 07:04PM	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation CNW Group
06:00PM	Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know Zacks
05:45PM	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Business Wire
12:10PM	Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report? Zacks
11:14AM	Teva's (TEVA) Schizophrenia Drug Gets CRL From the FDA Zacks
10:02AM	Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab Zacks
08:35AM	AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag Zacks
07:00AM	The Best Stocks to Invest $5,000 In Right Now Motley Fool
06:55AM	The Zacks Analyst Blog Highlights UnitedHealth Group, Danaher, Wells Fargo, Vertex Pharmaceuticals and Canadian Pacific Railway Zacks
Apr-19-22 11:52AM	Q1 Scorecard and Analyst Reports for UnitedHealth, Danaher & Wells Fargo Zacks
09:23AM	J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View Zacks
Apr-18-22 06:04AM	3 Fantastic Biotech Stocks to Buy in April Motley Fool
Apr-16-22 06:18AM	3 Reasons Vertex Pharmaceuticals Is a Top Stock to Buy Now Motley Fool

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 04	Sale	275.09	36	9,903	41,660	May 06 04:05 PM
Arbuckle Stuart A	EVP, COO	May 02	Sale	263.98	306	80,778	64,760	May 04 05:21 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	May 02	Sale	259.16	320	82,930	41,696	May 04 05:10 PM
Bhatia Sangeeta N.	Director	May 02	Sale	258.94	737	190,842	5,903	May 04 05:09 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	May 02	Sale	258.83	343	88,778	42,730	May 04 05:07 PM
Liu Joy	SVP, General Counsel	Apr 29	Sale	275.41	120	33,049	14,334	May 03 04:28 PM
Ambrose Kristen	SVP & Chief Accounting Officer	Apr 25	Sale	269.55	327	88,143	3,496	Apr 27 04:05 PM
Lee Yuchun	Director	Apr 18	Option Exercise	81.54	2,000	163,080	3,875	Apr 20 04:05 PM
Lee Yuchun	Director	Apr 18	Sale	284.23	2,000	568,467	1,875	Apr 20 04:05 PM
Lee Yuchun	Director	Apr 14	Option Exercise	81.54	2,000	163,080	3,875	Apr 18 04:05 PM
Lee Yuchun	Director	Apr 14	Sale	289.06	2,000	578,117	1,875	Apr 18 04:05 PM
Lee Yuchun	Director	Apr 13	Option Exercise	81.54	2,000	163,080	3,875	Apr 14 04:35 PM
LEIDEN JEFFREY M	Executive Chairman	Apr 13	Sale	289.04	15,789	4,563,653	74,160	Apr 14 04:35 PM
Lee Yuchun	Director	Apr 13	Sale	287.50	2,000	575,010	1,875	Apr 14 04:35 PM
Lee Yuchun	Director	Apr 12	Option Exercise	81.54	2,000	163,080	3,875	Apr 14 04:35 PM
Lee Yuchun	Director	Apr 12	Sale	281.03	2,000	562,051	1,875	Apr 14 04:35 PM
Lee Yuchun	Director	Apr 11	Option Exercise	81.54	2,000	163,080	3,875	Apr 12 04:07 PM
Lee Yuchun	Director	Apr 11	Sale	280.30	2,000	560,599	1,875	Apr 12 04:07 PM
MCGLYNN MARGARET G	Director	Apr 08	Option Exercise	127.54	5,000	637,700	6,099	Apr 12 04:05 PM
Bhatia Sangeeta N.	Director	Apr 08	Option Exercise	125.71	1,907	239,729	7,098	Apr 12 04:05 PM
Lee Yuchun	Director	Apr 08	Option Exercise	81.54	2,000	163,080	3,875	Apr 12 04:07 PM
Lee Yuchun	Director	Apr 08	Sale	278.57	2,000	557,141	1,875	Apr 12 04:07 PM
Bhatia Sangeeta N.	Director	Apr 08	Sale	280.20	1,907	534,341	5,191	Apr 12 04:05 PM
MCGLYNN MARGARET G	Director	Apr 08	Sale	280.22	5,000	1,401,080	1,099	Apr 12 04:05 PM
Lee Yuchun	Director	Apr 07	Option Exercise	81.54	2,000	163,080	3,875	Apr 08 05:57 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 07	Sale	276.18	561	154,935	42,782	Apr 08 04:34 PM
Lee Yuchun	Director	Apr 07	Sale	274.86	2,000	549,720	1,875	Apr 08 05:57 PM
Lee Yuchun	Director	Apr 06	Option Exercise	81.54	2,000	163,080	3,875	Apr 08 05:57 PM
Lee Yuchun	Director	Apr 06	Sale	271.62	2,000	543,243	1,875	Apr 08 05:57 PM
Lee Yuchun	Director	Apr 05	Option Exercise	81.54	2,000	163,080	3,875	Apr 06 04:59 PM
Lee Yuchun	Director	Apr 05	Sale	272.50	2,000	544,993	1,875	Apr 06 04:59 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 05	Sale	275.23	3,163	870,552	43,343	Apr 06 05:02 PM
Lee Yuchun	Director	Apr 04	Option Exercise	81.54	2,000	163,080	3,875	Apr 06 04:59 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Apr 04	Sale	267.71	562	150,452	46,506	Apr 06 05:02 PM
Lee Yuchun	Director	Apr 04	Sale	267.72	2,000	535,431	1,875	Apr 06 04:59 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Apr 01	Sale	264.76	2,582	683,602	43,620	Apr 05 04:06 PM
MCGLYNN MARGARET G	Director	Mar 31	Option Exercise	127.54	5,000	637,700	6,099	Apr 04 04:05 PM
MCGLYNN MARGARET G	Director	Mar 31	Sale	262.27	5,000	1,311,346	1,099	Apr 04 04:05 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Mar 17	Sale	250.11	2,833	708,572	47,356	Mar 21 04:15 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Mar 17	Sale	250.15	3,171	793,218	46,202	Mar 21 04:12 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Mar 17	Sale	250.06	2,122	530,627	48,412	Mar 21 04:10 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 25	Sale	230.95	325	75,058	50,189	Feb 28 05:27 PM
Tatsis Ourania	EVP, Chief Reg. & Quality Off.	Feb 18	Sale	231.00	519	119,889	53,104	Feb 22 05:03 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 18	Sale	230.97	4,312	995,949	49,687	Feb 22 04:51 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 14	Sale	232.02	2,444	567,057	57,438	Feb 16 04:05 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 11	Sale	235.02	2,297	539,837	59,882	Feb 14 04:11 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 02	Option Exercise	86.52	4,660	403,183	70,357	Feb 03 04:06 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Feb 02	Sale	251.47	4,660	1,171,842	65,697	Feb 03 04:06 PM
WAGNER CHARLES F JR	EVP & Chief Financial Officer	Feb 02	Sale	250.07	2,944	736,206	57,435	Feb 03 04:29 PM
Sanna Bastiano	EVP, Cell & Genetic Therapies	Feb 02	Sale	250.98	1,040	261,017	54,952	Feb 03 04:26 PM
MCGLYNN MARGARET G	Director	Jan 28	Option Exercise	127.54	5,000	637,700	6,099	Feb 01 04:09 PM
MCGLYNN MARGARET G	Director	Jan 28	Sale	241.79	5,000	1,208,960	1,099	Feb 01 04:09 PM
Sachdev Amit	EVP, Chief Patient Officer	Nov 15	Sale	187.19	51	9,547	31,928	Nov 16 04:07 PM
Arbuckle Stuart A	EVP, COO	Nov 15	Sale	187.26	3	562	41,103	Nov 16 04:05 PM
ALTSHULER DAVID	EVP, Global Research and CSO	Nov 15	Sale	187.22	34	6,365	33,589	Nov 16 04:04 PM
Kewalramani Reshma	CEO & President	Aug 19	Buy	195.65	10,000	1,956,492	73,754	Aug 23 08:30 AM
SACHS BRUCE I	Director	Aug 02	Buy	197.91	15,000	2,968,650	41,210	Aug 04 04:05 PM
Bhatia Sangeeta N.	Director	Jun 02	Sale	209.69	559	117,216	5,191	Jun 04 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience